Fisher & Paykel Healthcare Corporation Limited Ord Shares
FPH.NZXHealth Care
Fisher & Paykel Healthcare is a global leader in medical devices and systems for use in respiratory care and acute care, and in the treatment of obstructive sleep apnea. The company has a consistent growth strategy to provide an expanding range of innovative medical devices which can help to improve care and outcomes for patients in an increasing range of applications. Its products are sold to hospitals and healthcare facilities around the world through direct sales offices operations and a network of distributors that sell to hospitals, homecare providers and other manufacturers of medical devices. Formerly Fisher & Paykel Industries, Fisher & Paykel Healthcare arose from the separation of the major trading businesses of Fisher & Paykel Industries into Appliances and Healthcare in November 2001. The company's securities are listed in both New Zealand and Australia.
Market Data
$39.600
+0.0%$23.3B
49.6x
$0.798
1.85%
+0.1%
Latest Earnings
FPH reports strong revenue and profit growth for FY26
26 May 2026
Fisher & Paykel Healthcare delivered strong FY26 results with total operating revenue up 14% to NZ$2.31 billion and net profit after tax up 24% to NZ$468.5 million (28% in constant currency). The Hospital segment was the standout performer with 18% revenue growth to $1.51 billion, while Homecare grew 8% to $802.7 million. The company provided upbeat FY27 guidance with revenue of $2.45–$2.57 billion and NPAT of $500–$550 million, and lifted the full-year dividend 22% to 52.0 cents per share. Key points: Revenue grew 14% to NZ$2.31 billion (12% in constant currency), with Hospital segment up 18% to NZ$1.51 billion and Homecare up 8% to NZ$802.7 million; NPAT grew 24% to NZ$468.5 million (28% in constant currency), with operating margin expanding 235 bps to 27.6%; Gross margin improved 80 bps to 63.7% (122 bps in constant currency) driven by continuous improvement initiatives, despite ~90 bps headwind from US tariffs on NZ-sourced hospital products
Recent Announcements
Ongoing Disclosure Notice - Ordinary Shares
Justin Peter Callahan, Vice President of Sales & Marketing at Fisher & Paykel Healthcare Corporation Limited, acquired 142 ordinary shares on 1 July 2026 through the company's Employee Stock Purchase Plan at NZD 33.1882 per share, increasing his holding from 220,867 to 221,009 shares.
Capital Change Notice - North America ESPP
Fisher & Paykel Healthcare Corporation Limited issued 13,781 ordinary shares on 1 July 2026 at NZ$33.1882 per share to North American employees participating in the company's Employee Stock Purchase Plan, representing 0.00235% of total issued shares.
Notification of AUD FX Rate for FY26 Final Dividend
Fisher & Paykel Healthcare Corporation Limited has set the AUD foreign exchange rate at 0.8185 for the payment of its FY26 final dividend to Australian investors on 3 July 2026.
Notification of closing date for Director nominations
Fisher & Paykel Healthcare Corporation Limited has announced that its 2026 Annual Shareholders' Meeting will be held on 25 August 2026, with a closing date of 25 June 2026 for director nominations. The meeting will be held both online and in person at the company's East Tāmaki campus in Auckland, New Zealand.
Ongoing Disclosure Notice - Ordinary Shares
Director Graham Andrew McLean of Fisher & Paykel Healthcare Corporation Limited acquired 1,000 ordinary shares on 2 June 2026 at AUD 30.00 per share, increasing his beneficial interest (held via McLean Superfund A/C with Linda Farrell as co-trustee) from 3,900 to 4,900 shares.
FPH reports strong revenue and profit growth for FY26
Fisher & Paykel Healthcare delivered strong FY26 results with total operating revenue up 14% to NZ$2.31 billion and net profit after tax up 24% to NZ$468.5 million (28% in constant currency). The Hospital segment was the standout performer with 18% revenue growth to $1.51 billion, while Homecare grew 8% to $802.7 million. The company provided upbeat FY27 guidance with revenue of $2.45–$2.57 billion and NPAT of $500–$550 million, and lifted the full-year dividend 22% to 52.0 cents per share. Key points: Revenue grew 14% to NZ$2.31 billion (12% in constant currency), with Hospital segment up 18% to NZ$1.51 billion and Homecare up 8% to NZ$802.7 million; NPAT grew 24% to NZ$468.5 million (28% in constant currency), with operating margin expanding 235 bps to 27.6%; Gross margin improved 80 bps to 63.7% (122 bps in constant currency) driven by continuous improvement initiatives, despite ~90 bps headwind from US tariffs on NZ-sourced hospital products
SPH Notice - The Vanguard Group, Inc.
The Vanguard Group, Inc disclosed a change in substantial holding (5.001%).
SPH Notice - Pinnacle Investment Management Group Limited
Pinnacle Investment Management Group Limited disclosed a change in substantial holding (5.0145%).
FPH to announce full year results on 26 May 2026
Fisher & Paykel Healthcare Corporation Limited announced it will release its full year financial results for the year ended 31 March 2026 on Tuesday, 26 May 2026 at 9:00am NZST, followed by a conference call at 10:00am NZST with webcast access available.
Ongoing Disclosure Notice - Ordinary Shares
Justin Peter Callahan, Vice President - Sales & Marketing at Fisher & Paykel Healthcare Corporation Limited, acquired 129 ordinary shares on 1 April 2026 at NZD 31.2811 per share through the Employee Stock Purchase Plan, increasing his holding from 220,738 to 220,867 shares.
Get real-time alerts for FPH
Receive AI-powered earnings summaries and instant notifications when Fisher & Paykel Healthcare Corporation Limited Ord Shares releases results.
Register Free